This site is intended for health professionals only
Friday 26 April 2019
Share |

S-1 plus cisplatin holds hope for gastric cancer therapy

S-1 plus cisplatin holds promise of becoming a standard first-line treatment for patients with advanced gastric cancer, researchers have concluded.

The investigators presented findings from the phase III SPIRITS (S-1 Plus cisplatin versus S-1 In RCT In the Treatment for Stomach cancer) trial, published early online in Lancet Oncology.

S-1 (TS-1, Taiho Pharmaceuticals, Japan) is an orally active combination of tegafur (a prodrug converted by cells to fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades fluorouracil), and oteracil (which inhibits phosphorylation of fluorouracil in the GI tract, reducing GI toxic effects of fluorouracil).

The study involved chemotherapy-naive patients with advanced gastric cancer enrolled in 2002-4 at 38 centres in Japan.

They were randomised to receive either combination treatment with S-1 plus cisplatin, or S-1 alone.

The primary endpoint was overall survival and secondary endpoints were progression-free survival, proportions of responders, and safety.

An intention-to-treat analysis found that:

  • Median overall survival was longer in patients on combination treatment.
  • Progression-free survival was longer in patients on combination treatment.
  • Of 87 patients on combination treatment who had target tumours, one patient had a complete response and 46 patients partial responses.
  • Of 106 patients on S-1 alone who had target tumours, one patient had a complete response and 32 partial responses.
  • More grade 3 or 4 adverse events were reported in the combination treatment group.
  • There were no treatment-related deaths in either group.

The drug is currently used in Japan for treating gastric, colorectal, head and neck, non-small cell lung, metastatic breast and pancreatic cancers, and is in phase III clinical development in other countries.

Sanofi-Aventis is collaborating on and leading clinical development and commercialisation of S-1 in Europe and the USA.

Lancet

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine